Haemonetics
Stock Forecast, Prediction & Price Target
Haemonetics (HAE) stock Price Target by analysts
$120
Potential upside: 124.55%
Haemonetics price prediction
What is Haemonetics stock analysts` prediction?
Haemonetics stock forecast: Based on 1 Wall Street analysts` predicted price targets for Haemonetics in the last 3 months, the avarage price target is $120, with a high forecast of $NaN. The average price target represents a 124.55% change from the last price of $53.44.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Haemonetics stock Price Target by analysts
Full breakdown of analysts given Haemonetics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Andrew Cooper Raymond James | 0% 0/1 | 11 months ago | $120 124.55% upside | $74.83 | StreetInsider | Previous targets (0) |
Kristen Stewart C.L. King | 0% 0/1 | about 1 year ago | $116 117.06% upside | $73.26 | TheFly | Previous targets (0) |
Craig Bijou Bank of America Securities | 0% 0/1 | about 1 year ago | $85 59.05% upside | $71.62 | StreetInsider | Previous targets (0) |
Mike Matson Needham | 0% 0/1 | over 1 year ago | $112 109.58% upside | $83.41 | StreetInsider | Previous targets (0) |
Haemonetics Financial Estimates
Haemonetics Revenue Estimates
Haemonetics EBITDA Estimates
Haemonetics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 4/2/2022 | 4/1/2023 | 3/30/2024 | 3/30/2026 | 4/1/2026 | 3/30/2027 | 4/1/2027 |
Revenue
% change YoY
| $993.19M N/A | $1.16B 17.66% | $1.30B 12.01% | Avg: $1.47B Low: $1.46B High: $1.49B avg. 12.69% | Avg: $1.45B Low: $1.40B High: $1.50B avg. -1.63% | Avg: $1.60B Low: $1.58B High: $1.63B avg. 10.55% | Avg: $1.59B Low: $1.54B High: $1.65B avg. -0.64% |
Net Income
% change YoY
| $43.37M N/A | $115.40M 166.05% | $117.55M 1.86% | Avg: $216.87M Low: $192.73M High: $232.82M avg. 84.48% | Avg: $195.84M Low: $187.16M High: $230.87M avg. -9.69% | Avg: $287.37M Low: $241.05M High: $320.71M avg. 46.73% | Avg: $251.75M Low: $238.07M High: $249.90M avg. -12.39% |
EBITDA
% change YoY
| $169.47M N/A | $249.34M 47.12% | $265.57M 6.51% | Avg: $309.19M Low: $307.04M High: $313.48M avg. 16.42% | Avg: $294.30M Low: $285.39M High: $305.05M avg. -4.81% | Avg: $336.22M Low: $331.63M High: $342.46M avg. 14.24% | Avg: $323.27M Low: $313.47M High: $335.07M avg. -3.85% |
EPS
% change YoY
| $0.85 N/A | $2.27 167.05% | $2.32 2.20% | Avg: $4.03 Low: $3.75 High: $4.53 avg. 73.70% | Avg: $3.97 Low: $3.64 High: $4.49 avg. -1.61% | Avg: $5.57 Low: $4.69 High: $6.24 avg. 40.56% | Avg: $4.75 Low: $4.63 High: $4.86 avg. -14.86% |
Operating Expenses
% change YoY
| $433.77M N/A | $459.06M 5.82% | $526.66M 14.72% | Avg: $472.14M Low: $468.86M High: $478.69M avg. -10.35% | Avg: $461.60M Low: $447.61M High: $478.45M avg. -2.23% | Avg: $513.40M Low: $506.40M High: $522.95M avg. 11.22% | Avg: $507.03M Low: $491.66M High: $525.53M avg. -1.24% |
FAQ
What is Haemonetics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 27.28% in 2026-2027.
We have gathered data from 4 analysts. Their low estimate is 192.73M, average is 216.87M and high is 232.82M.
What is Haemonetics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 5.24% in 2026-2027.
We have gathered data from 5 analysts. Their low revenue estimate is $1.46B, average is $1.47B and high is $1.49B.
What is Haemonetics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 24.44% in 2026-2027.
We have gathered data from 4 analysts. Their low earnings per share estimate is $3.75, average is $4.03 and high is $4.53.
What is the best performing analyst?
In the last twelve months 1 analysts have been covering Haemonetics stock. The most successful analyst is Andrew Cooper.